Evidence map›Paper›PMID 34510840›Full record

ArticleHepatology communications2021

Hepatic Adenosine Triphosphate Reduction Through the Short-Chain Fatty Acids-Peroxisome Proliferator-Activated Receptor γ-Uncoupling Protein 2 Axis Alleviates Immune-Mediated Acute Hepatitis in Inulin-Supplemented Mice.

Akihiro Yamaguchi, Toshiaki Teratani, Po-Sung Chu, Takahiro Suzuki, Nobuhito Taniki, Yohei Mikami, Shunsuke Shiba, Rei Morikawa, Takeru Amiya, Ryo Aoki and 2 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Gut microbes
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Akihiro YamaguchiDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Toshiaki TerataniDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Po-Sung ChuDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Takahiro SuzukiDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Nobuhito TanikiDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Yohei MikamiDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Shunsuke ShibaDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Rei MorikawaDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Takeru AmiyaDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Ryo AokiDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Takanori KanaiDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.
Nobuhiro NakamotoDivision of Gastroenterology and HepatologyDepartment of Internal MedicineKeio University School of MedicineTokyoJapan.ORCID 0000-0001-5203-7444
Keio University · JPMitsubishi Group (Japan) · JP

Funding

Keio Medical Fund N/A
6 · The paper itself

Abstract

How liver tolerance is disrupted in immune-mediated liver injury is currently unclear. There is also insufficient information available regarding susceptibility, precipitation, escalation, and perpetuation of autoimmune hepatitis. To explore how dietary fiber influences hepatic damage, we applied the concanavalin A (ConA)-induced acute immune-mediated liver injury model in mice fed a diet supplemented with 6.8% inulin, a water-soluble fermentable fiber. Twelve hours after ConA administration, inulin-supplemented diet-fed mice demonstrated significantly alleviated hepatic damage histologically and serologically, with down-regulation of hepatic interferon-γ and tumor necrosis factor and reduced myeloperoxidase (MPO)-producing neutrophil infiltration. Preconditioning with an inulin-supplemented diet for 2 weeks significantly reduced hepatic adenosine triphosphate (ATP) content; suramin, a purinergic P2 receptor antagonist, abolished the protective effect. Of note, the portal plasma derived from mice fed the inulin-supplemented diet significantly alleviated ConA-induced immune-mediated liver injury. Mechanistically, increased portal short-chain fatty acid (SCFA) levels, such as those of acetate and butyrate, by inulin supplementation leads to up-regulation of hepatic γ-type peroxisome proliferator-activated receptor (Pparg) and uncoupling protein 2 (Ucp2), which uncouples mitochondrial ATP synthesis downstream of PPARγ. Pparg down-regulating small interfering RNA cancelled the protective effect of inulin supplementation against MPO-producing neutrophil infiltration and the subsequent immune-mediated liver injury, suggesting that the SCFA-PPARγ-UCP2 axis plays a key role in the protective effect by inulin supplementation. Moreover, significant changes in the gut microbiota, including increased operational taxonomic units in genera Akkermansia and Allobaculum, also characterized the protective effect of the inulin-supplemented diet. Conclusion: There is a possible unraveled etiopathophysiological link between the maintenance of liver tolerance and dietary fiber. The SCFA-PPARγ-UCP2 axis may provide therapeutic targets for immune-mediated liver injury in the future.

Identifiers

PMID34510840
PMCPMC8435281
OpenAlexW3173028714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.